Avicanna unit ships 1st organic CBG flower to Australia

Executive Summary

• Avicanna Inc.'s majority-owned subsidiary, Santa Marta Golden Hemp SAS (SMGH), has successfully completed its first commercial export of CBG-dominant cannabis flower to Australia.
• The export validates SMGH's two-year investment in process development, infrastructure, and quality systems, positioning the facility for consistent, standardized commercial-scale production of cannabinoid-specific chemotypes compliant with international regulatory standards.
• Avicanna's global commercial footprint expands significantly, with SMGH now supplying products to 21 international markets and Avicanna products reaching 24 markets globally, leveraging proprietary cultivars and established operational advantages in Colombia.

Key Details

• Export Milestone: First commercial export of CBG-dominant cannabis flower completed to Australia via SMGH.
• Market Expansion: SMGH has now supplied products into 21 international markets; Avicanna products have reached 24 markets globally.
• Proprietary Genetics: The shipment includes SMGH's proprietary CBG cultivar, part of a registered genetic portfolio in Colombia.
• Facility Capacity & Yield: SMGH facility contains approximately 300,000 square feet of cultivation space, 300 kilograms of extraction capacity, and a current annual yield of approximately 26,400 kg.
• Certifications & Compliance: SMGH holds Good Agricultural and Collection Practices (GACP) and USDA National Organic Program certifications for its hemp cultivars, aligning operations with international regulatory expectations for APIs and raw materials.
• Operational Advantages: Colombian equatorial conditions enable year-round cultivation with controlled environmental parameters, supporting consistent production cycles, batch uniformity, and cost efficiencies.
• Supply Chain Integration: SMGH's Aureus-branded raw materials and APIs (CBD, CBG, THC) feed directly into Avicanna's consumer retail, medical cannabis, and pharmaceutical pipeline, while also supplying external international partners for research and manufacturing.
• Strategic Foundation: Two years of dedicated investment in infrastructure, quality systems, and regulatory alignment have established SMGH's readiness for long-term participation in international medical cannabis and pharmaceutical markets.